# STAT6

Source: https://onco.cc/targets/stat6/  
OnCo record `stat6` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

STAT6 (Signal transducer and activator of transcription 6) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Non-Hodgkin lymphoma and Diffuse large B-cell lymphoma.

## Summary

Carries out a dual function: signal transduction and activation of transcription. Involved in IL4/interleukin-4- and IL3/interleukin-3-mediated signalling.

CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.58 (direct and indirect evidence; datatypes literature 0.98, animal model 0.31, genetic association 0.08, somatic mutation 0.89). IntOGen calls it a driver in 4 cohorts (4 activating, 0 loss-of-function), covering Diffuse Large B-Cell Lymphoma, NOS, Malignant Lymphoma, Non-Hodgkin Lymphoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: signal transducer and activator of transcription 6; Signal transducer and activator of transcription 6; D12S1644; IL-4-STAT
- Tags: cancer-genes-wave
- Symbol: STAT6
- Class: oncogene
- Biology: Carries out a dual function: signal transduction and activation of transcription. Involved in IL4/interleukin-4- and IL3/interleukin-3-mediated signalling. Location: Cytoplasm; Nucleus (UniProt). Locus 12q13.3 (HGNC).
- Where found: Non-Hodgkin lymphoma: Open Targets association 0.65 with non-Hodgkin lymphoma (MONDO_0018908); IntOGen driver in 2 cohorts (MLYM, NHL); Diffuse large B-cell lymphoma: Open Targets association 0.51 with diffuse large B-cell lymphoma (MONDO_0018905); CIViC evidence names this disease

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 4 cohorts; CIViC holds 1 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:11368: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11368
- UniProt P42226: https://www.uniprot.org/uniprotkb/P42226/entry
- NCBI Gene 6778: https://www.ncbi.nlm.nih.gov/gene/6778
- Ensembl ENSG00000166888: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000166888

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/stat6.json